Recent News

• 09.04.2025 - Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
• 09.02.2025 - Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 08.14.2025 - Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
• 07.31.2025 - Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
• 07.01.2025 - Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Recent Filings

• 08.18.2025 - EX-99.1 EX-99.1
• 08.18.2025 - 8-K Current report
• 08.15.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.15.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.15.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.15.2025 - 8-K Current report
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.31.2025 - 8-K Current report
• 07.31.2025 - EX-99.1 EX-99.1
• 06.20.2025 - 4 Statement of changes in beneficial ownership of securities